HITGEN INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.35 CNY | +2.85% |
|
+14.99% | -10.94% |
| 04-24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2023 | 372M 51.33M 4.09B | Sales 2024 * | 436M 60.22M 4.8B | Capitalization | 5.33B 737M 58.7B |
|---|---|---|---|---|---|
| Net income 2023 | 43M 5.94M 473M | Net income 2024 * | 50M 6.91M 550M | EV / Sales 2023 | 16.1 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 12.2 x |
| P/E ratio 2023 |
136
x | P/E ratio 2024 * |
105
x | Employees | 508 |
| Yield 2023 |
0.33% | Yield 2024 * |
0.15% | Free-Float | 33.76% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.85% | ||
| 1 week | +14.99% | ||
| Current month | +0.53% | ||
| 1 month | +0.53% | ||
| 3 months | +9.70% | ||
| 6 months | -7.61% | ||
| Current year | -10.94% |
1 week
11.87
13.37
1 month
10.8113.95
Current year
8.8517.62
1 year
8.8519.35
3 years
8.8533.19
5 years
8.8561.99
10 years
8.8561.99
| Managers | Title | Age | Since |
|---|---|---|---|
Jin Li
CEO | Chief Executive Officer | 61 | 21/02/12 |
Eliza Liu
DFI | Director of Finance/CFO | 54 | 26/04/23 |
Barry A Morgan
CTO | Chief Tech/Sci/R&D Officer | 77 | 31/05/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yun Pei Guo
BRD | Director/Board Member | 76 | 26/05/22 |
Lin Wang
BRD | Director/Board Member | 56 | 25/05/18 |
Yong Cun Chen
BRD | Director/Board Member | 59 | 23/03/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 13.35 | +2.85% | 5,991,783 |
| 26/04/24 | 12.98 | +3.02% | 5,932,684 |
| 25/04/24 | 12.6 | +2.86% | 8,003,123 |
| 24/04/24 | 12.25 | +2.94% | 3,862,256 |
| 23/04/24 | 11.9 | +2.50% | 4,564,656 |
End-of-day quote Shanghai S.E., April 28, 2024
More quotes
HitGen Inc is a China-based company mainly engaged in the early research and development of original innovative drugs. The Company focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The Company mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The Company conducts its businesses within the domestic market and to overseas markets.
Calendar
25/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.35
CNY
Average target price
16
CNY
Spread / Average Target
+19.85%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.94% | 715M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- 688222 Stock
